T. Rowe Price Associates
ELV icon

T. Rowe Price Associates’s Elevance Health ELV Stock Holding History

T. Rowe Price Associates’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-58,000
Closed -$5.36M – 2503
2013
Q4 		$5.36M Buy
+58,000
New +$5.15M ﹤0.01% 1420

Other funds holding ELV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

T. Rowe Price Associates's ELV Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Elevance Health (ELV) stake by 36% in Q1 2026, selling an estimated $887M and leaving 4,746,585 shares worth $1.39B. The position accounts for 0.16% of the portfolio, ranked #125.

T. Rowe Price Associates first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.53B in Q4 2022. 1,466 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • T. Rowe Price Associates held 4,746,585 shares of Elevance Health worth $1.39B as of Q1 2026.
  • T. Rowe Price Associates sold 2,699,600 Elevance Health shares in Q1 2026, an estimated $887M.
  • Elevance Health made up 0.16% of T. Rowe Price Associates's portfolio in Q1 2026, its #125 holding.
  • T. Rowe Price Associates first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Elevance Health position peaked at $6.53B in Q4 2022.
  • 1,466 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.